<Suppliers Price>

Bisacodyl

Names

[ CAS No. ]:
603-50-9

[ Name ]:
Bisacodyl

[Synonym ]:
LA96A
laco
neolax
zetrax
durolax
laxine
EINECS 210-044-4
MFCD00038039
ivilax
Bicol
deficol
Laxans

Biological Activity

[Description]:

Bisacodyl is a stimulant laxative drug that works directly on the colon to produce a bowel movement.Target: OthersBisacodyl is an organic compound that is used as a stimulant laxative drug. Bisacodyl (20 mg/kg) results in a decrease in AQP3 protein expression and increased mRNA expression level of TNF-α in the colon of rats [1]. Bisacodyl inhibits water absorption in rat jejunum, ileum, and colon, the degree of inhibition is linearly related to the logarithm of the bisacodyl concentration over the range of 0.05 mg to 2.0 mg per 100 mL [2]. Bisacodyl (10 mg/kg, intragastrically) induces a significant decrease in jejunal NOS activity in rats. Bisacodyl (10 mg/kg, intragastrically) increases the distance traveled by the marker in all time periods [3]. Bisacodyl (5.9 mg/kg) decreases significantly jejunal and colonic (Na + K) ATPase activity as compared to saline-treated rats. Bisacodyl (5.9 mg/kg) increases significantly jejunal and colonic PGE2 content and stimulates jejunal and colonic adenyl cyclase activity as compared to those in control rats without affecting cAMP content [4]. Bisacodyl (4.3 mg/kg) coupled with AOM increases the number of crypt per focus, but not the number of tumors in rats. Bisacodyl (43 mg/kg) significantly increases the number of crypt per focus and tumors in rats [5].

[Related Catalog]:

Signaling Pathways >> Others >> Others
Research Areas >> Metabolic Disease

[References]

[1]. Ikarashi, N., et al., The laxative effect of bisacodyl is attributable to decreased aquaporin-3 expression in the colon induced by increased PGE2 secretion from macrophages. Am J Physiol Gastrointest Liver Physiol, 2011. 301(5): p. G887-95.

[2]. Saunders, D.R., et al., Effect of bisacodyl on the structure and function of rodent and human intestine. Gastroenterology, 1977. 72(5 Pt 1): p. 849-56.

[3]. Karmeli, F., R. Stalnikowicz, and D. Rachmilewitz, Effect of colchicine and bisacodyl on rat intestinal transit and nitric oxide synthase activity. Scand J Gastroenterol, 1997. 32(8): p. 791-6.

[4]. Rachmilewitz, D., F. Karmeli, and E. Okon, Effects of bisacodyl on cAMP and prostaglandin E2 contents, (Na + K) ATPase, adenyl cyclase, and phosphodiesterase activities of rat intestine. Dig Dis Sci, 1980. 25(8): p. 602-8.

[5]. Borrelli, F., et al., Effect of bisacodyl and cascara on growth of aberrant crypt foci and malignant tumors in the rat colon. Life Sci, 2001. 69(16): p. 1871-7.


[Related Small Molecules]

Captisol | Cyclosporin A | H2DCFDA | 0MPTP hydrochloride | GW4869 | Etomoxir | TD139 | Mitoquinone mesylate | GSK2795039 | JC-1 | BAPTA-AM | AP 20187 | Setanaxib (GKT137831) | D-Luciferin | Crotaline

Chemical & Physical Properties

[ Density]:
1.2 g/cm3

[ Boiling Point ]:
492ºC

[ Melting Point ]:
131 - 135ºC

[ Molecular Formula ]:
C22H19NO4

[ Molecular Weight ]:
361.39100

[ Exact Mass ]:
361.13100

[ PSA ]:
65.49000

[ LogP ]:
4.11240

[ Storage condition ]:
2-8°C

[ Stability ]:
Stable. Incompatible with strong oxidizing agents.

MSDS

Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :
SM8750000
CHEMICAL NAME :
Phenol, 4,4'-(2-pyridylmethylene)di-, diacetate (ester)
CAS REGISTRY NUMBER :
603-50-9
BEILSTEIN REFERENCE NO. :
0323727
LAST UPDATED :
199701
DATA ITEMS CITED :
11
MOLECULAR FORMULA :
C22-H19-N-O4
MOLECULAR WEIGHT :
361.42
WISWESSER LINE NOTATION :
T6NJ BYR DOV1&R DOV1

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
4320 mg/kg
TOXIC EFFECTS :
Behavioral - altered sleep time (including change in righting reflex) Gastrointestinal - other changes Blood - changes in spleen
REFERENCE :
TXAPA9 Toxicology and Applied Pharmacology. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1959- Volume(issue)/page/year: 2,243,1960
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
17500 mg/kg
TOXIC EFFECTS :
Behavioral - ataxia Lungs, Thorax, or Respiration - respiratory stimulation Blood - hemorrhage
REFERENCE :
TXAPA9 Toxicology and Applied Pharmacology. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1959- Volume(issue)/page/year: 2,243,1960
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
80 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
TXAPA9 Toxicology and Applied Pharmacology. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1959- Volume(issue)/page/year: 2,243,1960
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
>15 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: -,854,1990
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
40 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 3,19,1953
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Mammal - cat
DOSE/DURATION :
40 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 3,19,1953
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - rabbit
DOSE/DURATION :
40 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 3,19,1953 *** REVIEWS *** TOXICOLOGY REVIEW DAPOAG Deutsche Apotheker. (Postfach 1650, 6370 Oberusel/Taunas, Fed. Rep. Ger.) V.1- 1949- Volume(issue)/page/year: 27,151,1975 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOHS - National Occupational Hazard Survey (1974) NOHS Hazard Code - A1651 No. of Facilities: 86 (estimated) No. of Industries: 1 No. of Occupations: 1 No. of Employees: 431 (estimated) NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - A1651 No. of Facilities: 132 (estimated) No. of Industries: 2 No. of Occupations: 8 No. of Employees: 2964 (estimated) No. of Female Employees: 1874 (estimated)

Safety Information

[ Symbol ]:

GHS07

[ Signal Word ]:
Warning

[ Hazard Statements ]:
H315-H319-H335

[ Precautionary Statements ]:
P305 + P351 + P338

[ Personal Protective Equipment ]:
dust mask type N95 (US);Eyeshields;Gloves

[ Hazard Codes ]:
Xi:Irritant

[ Risk Phrases ]:
R22;R36/37/38

[ Safety Phrases ]:
S26-S36

[ RIDADR ]:
NONH for all modes of transport

[ WGK Germany ]:
3

[ RTECS ]:
SM8750000

[ HS Code ]:
2942000000

Synthetic Route

Precursor & DownStream

Customs

[ HS Code ]: 2933399090

[ Summary ]:
2933399090. other compounds containing an unfused pyridine ring (whether or not hydrogenated) in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

Articles

[Bowel preparation for colonoscopy: comparative study using Boston Bowel Preparation Scale].

Acta Gastroenterol. Latinoam. 42(3) , 186-92, (2012)

Most comparative studies on different preparations for colonic cleanliness use unvalidated scales with terms as "excellent," "good," "fair," and "poor" which lack standardized definitions. The Boston ...

Suitability of κ-carrageenan pellets for the formulation of multiparticulate tablets with modified release.

Int. J. Pharm. 409(1-2) , 9-18, (2011)

κ-Carrageenan is a novel pelletisation aid with high formulation robustness and quick disintegration leading to fast drug release unlike the matrix-like release from non-disintegrating microcrystallin...

Optimizing adequacy of bowel cleansing for colonoscopy: recommendations from the US multi-society task force on colorectal cancer.

Gastroenterology 147(4) , 903-24, (2014)


More Articles


Related Compounds